Patients with type 2 diabetes mellitus (T2DM) are exposed to a high risk of atherosclerotic
cardiovascular disease, heart failure and chronic kidney disease. The incidence of these …

Type 2 diabetes mellitus (T2DM) is a highly prevalent health condition in the aging
population. Older adults with T2DM have higher risks of cardiovascular disease, heart failure …

Aim Sodium‐glucose cotransporter 2 inhibitors (SGLT2is) are particularly effective in
preventing adverse outcomes of heart failure and chronic kidney disease, which are highly …

Sodium‐glucose cotransporter 2 inhibitors (SGLT2is) have been shown in cardiovascular
outcome trials to reduce the risk of heart failure and major adverse cardiovascular as well as …

Atherosclerotic cardiovascular disease (ASCVD), heart failure (HF) and chronic kidney
disease (CKD) are major complications of type 2 diabetes (T2DM). The objectives of …

Objective Sodium-glucose cotransporter-2 inhibitors (SGLT2Is) reduce cardio-metabolic and
renal outcomes in patients with type 2 diabetes (T2D) but their efficacy and safety in older or …

Type 2 Diabetes Mellitus (T2DM) is associated with an elevated incidence of cardiovascular
and renal diseases, responsible for mortality rates significantly higher than in the general …

Results Cardiovascular disease represents a large health burden in patients with diabetes.
The prevention of cardiovascular events is a major concern in the treatment of patients with …

The burden of diabetic kidney disease is rising rapidly worldwide, and new therapies are of
vital importance to reduce the risk of kidney failure and major cardiovascular events. Of the …

Despite remarkable advances in diabetes care, patients with type 2 diabetes are still
burdened by higher morbidity and mortality than non-diabetic individuals. Atherosclerotic …